- The validation confirms that the submission is sufficiently complete to begin the formal review process for the non-invasive, once-daily epicutaneous patch to treat peanut allergies in children ages 4 to 11 years.
Slingshot members are tracking this event:
DBV Technologies (DBVT) Announces Marketing Authorization Application Approval for Viaskin Peanut by European Medicines Agency
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Nov 02, 2020
Don’t see a project related to the catalyst you care about?
Related Keywords Viaskin, Viaskin Peanut